Omega Therapeutics

Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.

Novo Nordisk

Omega Therapeutics shares surged more than 100% after it was announced it is partnering with Danish healthcare company Novo Nordisk (NYSE:NVO) to develop novel treatment approaches for cardiometabolic diseases. Novo Nordisk (NYSE:NVO) said that its collaboration with Omega will develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management.

Omega Therapeutics shares surge on obesity collaboration with Novo Nordisk

Bagsværd, Denmark, Cambridge, Mass., and Somerville, Mass. 4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) and Cellarity Inc. today announced that Novo Nordisk has entered into separate research collaborations with each company. The Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. The Cellarity collaboration aims to unravel novel biological drivers of MASH and will leverage Cellarity's platform to develop a small molecule therapy against this disease.

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 9:45 a.m. PT (12:45 p.m. ET).

Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023, at 9:30 a.m. ET.

Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 12:00 p.m. ET.

Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference

First-ever demonstration of sustained pre-transcriptional upregulation of gene expression by an epigenomic controller in both in vitro and in vivo models of liver fibrosis

Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent Company progress.

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 12:30 p.m. GMT (7:30 a.m. ET).

Omega Therapeutics to Participate in The Jefferies London Healthcare Conference

Coordinated modulation of epigenetic profile of CXCL1-8 genes with corresponding downregulation of gene expression and protein levels, and inhibition of immune cell recruitment, shown in multiple models of inflammatory disease

Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller

Combination of a MYC-targeting epigenomic controller with immune checkpoint or EGFR inhibitor enhanced anti-tumor activity in models of NSCLC Combination of a MYC-targeting epigenomic controller with immune checkpoint or EGFR inhibitor enhanced anti-tumor activity in models of NSCLC

Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data demonstrating the potential of epigenomic controllers for the treatment of inflammatory and fibrotic liver diseases at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14.

Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD's The Liver Meeting® 2023

Cutera

Revolution Medicines

Volitionrx Limited

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Are Preparing To Pump This Quarter - Omega Therapeutics (NASDAQ:OMGA), Cutera (NASDAQ:CUTR)

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data supporting the potential of OTX-2101, a c-MYC (MYC)-targeting epigenomic controller being developed for the treatment of non-small cell lung cancer (NSCLC), at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts, October 11 – 15, 2023.

Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

It seems to take a lot to impress those invested in Omega Therapeutics Inc. The shares fell after the biotech reported what on the face of it were positive early results from a phase I/II trial of its drug candidate.

Omega Therapeutics: Good news met with share markdown

All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state change and robust downregulation in expression of c-MYC , a historically ‘undruggable' target

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will host a conference call and webcast to discuss preliminary clinical data from the ongoing Phase 1/2 MYCHELANGELO™ I trial of OTX-2002 on Tuesday, September 26, 2023, at 8:00 a.m. ET.

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that members of management will participate in fireside chats at two upcoming investor conferences.

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

Denali Therapeutics

Foghorn Therapeutics

Seres Therapeutics

Moderna

Sana Biotechnology

CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer.

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that Chris Schade has been appointed as Chairman of the Board, succeeding Noubar Afeyan, Ph.D. In addition, Michelle C. Werner will join Omega's Board to support the Company's growth.

Omega Therapeutics Announces Updates to its Board of Directors

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent Company progress.

Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

OMGA has an early stage program targeting various cancers using epigenetics. They are backed by a VC and have a decent cash runway. Though too early stage for my liking, OMGA is interesting.

Omega Therapeutics: Working In Epigenetic Anti-Cancer Programs

Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise

Omega Therapeutics Appoints Chris Schade to its Board of Directors

Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively The company emerges after two years of platform development with an initial commitment of $50 million from Flagship Pioneering Empress has identified and characterized 15 potential small molecule drugs in less than two years; it expects to file multiple Investigational New Drug (IND) applications within the next 24 months Murray McKinnon, Ph.D., former Global Head of J&J's World Without Disease Accelerator and Head of Immunology Discovery within Janssen Pharmaceuticals, appointed Chief Scientific Officer CAMBRIDGE, Mass.

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointments of Paul E. Cayer as Chief Financial Officer and Omega Therapeutics President and CEO, Mahesh Karande to the Board of Directors.

Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data demonstrating the effect of MYC-targeting Omega Epigenomic Controllers™ (OECs) on the tumor microenvironment (TME) and immunotherapy responses in hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC) models in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois, June 2 – 6, 2023.

Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting

News for Omega Therapeutics Stock (OMGA)